These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Regional Overlap of Pathologies in Lewy Body Disorders. Colom-Cadena M; Grau-Rivera O; Planellas L; Cerquera C; Morenas E; Helgueta S; Muñoz L; Kulisevsky J; Martí MJ; Tolosa E; Clarimon J; Lleó A; Gelpi E J Neuropathol Exp Neurol; 2017 Mar; 76(3):216-224. PubMed ID: 28395086 [TBL] [Abstract][Full Text] [Related]
11. Accumulation of beta-synuclein in cortical neurons is associated with autophagy attenuation in the brains of dementia with Lewy body patients. Evans T; Kok WL; Cowan K; Hefford M; Anichtchik O Brain Res; 2018 Feb; 1681():1-13. PubMed ID: 29278715 [TBL] [Abstract][Full Text] [Related]
12. α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Sorrentino ZA; Giasson BI; Chakrabarty P Acta Neuropathol; 2019 Jul; 138(1):1-21. PubMed ID: 30798354 [TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease. Ito S; Takao M; Hatsuta H; Kanemaru K; Arai T; Saito Y; Fukayama M; Murayama S Int J Clin Exp Pathol; 2014; 7(4):1714-23. PubMed ID: 24817969 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. Anderson JP; Walker DE; Goldstein JM; de Laat R; Banducci K; Caccavello RJ; Barbour R; Huang J; Kling K; Lee M; Diep L; Keim PS; Shen X; Chataway T; Schlossmacher MG; Seubert P; Schenk D; Sinha S; Gai WP; Chilcote TJ J Biol Chem; 2006 Oct; 281(40):29739-52. PubMed ID: 16847063 [TBL] [Abstract][Full Text] [Related]
16. α-synuclein phosphorylation and truncation are normal events in the adult human brain. Muntané G; Ferrer I; Martinez-Vicente M Neuroscience; 2012 Jan; 200():106-19. PubMed ID: 22079575 [TBL] [Abstract][Full Text] [Related]
17. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Bosco DA; Fowler DM; Zhang Q; Nieva J; Powers ET; Wentworth P; Lerner RA; Kelly JW Nat Chem Biol; 2006 May; 2(5):249-53. PubMed ID: 16565714 [TBL] [Abstract][Full Text] [Related]
18. Effect of topographical distribution of α-synuclein pathology on TDP-43 accumulation in Lewy body disease. Yokota O; Davidson Y; Arai T; Hasegawa M; Akiyama H; Ishizu H; Terada S; Sikkink S; Pickering-Brown S; Mann DM Acta Neuropathol; 2010 Dec; 120(6):789-801. PubMed ID: 20669025 [TBL] [Abstract][Full Text] [Related]
19. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051 [TBL] [Abstract][Full Text] [Related]
20. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? Vernon AC; Ballard C; Modo M Brain Res Rev; 2010 Oct; 65(1):28-55. PubMed ID: 20685363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]